Analysis of metabolites in human gut: illuminating the design of gut-targeted drugs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI (2007) The human microbiome project. Nature 449(7164):804–810. https://doi.org/10.1038/nature06244
Almeida A, Mitchell AL, Boland M, Forster SC, Gloor GB, Tarkowska A, Lawley TD, Finn RD (2019) A new genomic blueprint of the human gut microbiota. Nature 568(7753):499–504. https://doi.org/10.1038/s41586-019-0965-1
Proctor LM, Creasy HH, Fettweis JM, Lloyd-Price J, Mahurkar A, Zhou W, Buck GA, Snyder MP, Strauss JF, Weinstock GM, White O, Huttenhower C (2019) The integrative HMP (iHMP) research network consortium. Integrative Human Microbiome Project Nature 569(7758):641–648. https://doi.org/10.1038/s41586-019-1238-8
Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R (2018) Current understanding of the human microbiome. Nat Med 24(4):392–400. https://doi.org/10.1038/nm.4517
Fan Y, Pedersen O (2021) Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 19(1):55–71. https://doi.org/10.1038/s41579-020-0433-9
Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z, Su L, Li X, Li X, Li J, Xiao L, Huber-Schönauer U, Niederseer D, Xu X, Al-Aama JY, Yang H, Wang J, Kristiansen K, Arumugam M, Tilg H, Datz C, Wang J (2015) Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nature Commun. https://doi.org/10.1038/ncomms7528
Javdan B, Lopez JG, Chankhamjon P, Lee Y-CJ, Hull R, Wu Q, Wang X, Chatterjee S, Donia MS (2020) Personalized mapping of drug metabolism by the human gut microbiome. Cell 181(7):1661-1679.e22. https://doi.org/10.1016/j.cell.2020.05.001
Jeganathan NA, Davenport ER, Yochum GS, Koltun WA (2021) The microbiome of diverticulitis. Curr Opin Physio 22:100452. https://doi.org/10.1016/j.cophys.2021.06.006
Lavelle A, Sokol H (2020) Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 17(4):223–237. https://doi.org/10.1038/s41575-019-0258-z
Lee W-J, Hase K (2014) Gut microbiota-generated metabolites in animal health and disease. Nat Chem Biol 10(6):416–424. https://doi.org/10.1038/nchembio.1535
Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY (2018) The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell 173(7):1728-1741.e13. https://doi.org/10.1016/j.cell.2018.04.027
Funabashi M, Grove TL, Wang M, Varma Y, McFadden ME, Brown LC, Guo C, Higginbottom S, Almo SC, Fischbach MA (2020) A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature 582(7813):566–570. https://doi.org/10.1038/s41586-020-2396-4
Donia MS, Fischbach MA (2015) Small molecules from the human microbiota. Science. https://doi.org/10.1126/science.1254766
Henke MT, Clardy J (2019) Molecular messages in human microbiota. Science 366(6471):1309–1310. https://doi.org/10.1126/science.aaz4164
Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy MP, Bodai Z, Belda-Ferre P, Tripathi A, Chung LK, Downes M, Welch RD, Quinn M, Humphrey G, Panitchpakdi M, Weldon KC, Aksenov A, da Silva R, Avila-Pacheco J, Clish C, Bae S, Mallick H, Franzosa EA, Lloyd-Price J, Bussell R, Thron T, Nelson AT, Wang M, Leszczynski E, Vargas F, Gauglitz JM, Meehan MJ, Gentry E, Arthur TD, Komor AC, Poulsen O, Boland BS, Chang JT, Sandborn WJ, Lim M, Garg N, Lumeng JC, Xavier RJ, Kazmierczak BI, Jain R, Egan M, Rhee KE, Ferguson D, Raffatellu M, Vlamakis H, Haddad GG, Siegel D, Huttenhower C, Mazmanian SK, Evans RM, Nizet V, Knight R, Dorrestein PC (2020) Global chemical effects of the microbiome include new bile-acid conjugations. Nature 579(7797):123–129. https://doi.org/10.1038/s41586-020-2047-9
Lavelle A, Sokol H (2020) Gut Microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 17(4):223–237. https://doi.org/10.1038/s41575-019-0258-z
Silpe JE, Balskus EP (2021) Deciphering human microbiota-host chemical interactions. ACS Cent Sci 7(1):20–29. https://doi.org/10.1021/acscentsci.0c01030
Saha S, Rajpal DK, Brown JR (2016) human microbial metabolites as a source of new drugs. Drug Discovery Today 21(4):692–698. https://doi.org/10.1016/j.drudis.2016.02.009
Chavira A, Belda-Ferre P, Kosciolek T, Ali F, Dorrestein PC, Knight R (2019) The microbiome and its potential for pharmacology. In: Barrett JE, Page CP, Michel MC (eds) Concepts and principles of pharmacology: 100 years of the handbook of experimental pharmacology handbook of experimental pharmacology. Springer International Publishing, Cham
Nuzzo A, Brown JR (2020) Microbiome metabolite mimics accelerate drug discovery. Trends Mol Med 26(5):435–437. https://doi.org/10.1016/j.molmed.2020.03.006
Harris VC, Haak BW, Boele Van Hensbroek M, Wiersinga WJ (2017) The intestinal microbiome in infectious diseases the clinical relevance of a rapidly emerging field. Open Forum Infect Dis 4(3):144. https://doi.org/10.1093/ofid/ofx144
Maciel-Fiuza MF, Muller GC, Campos DMS (2023) Role of gut microbiota in infectious and inflammatory diseases. Front Microbiol 14:1098386. https://doi.org/10.3389/fmicb.2023.1098386
Delzenne NM, Neyrinck AM, Bäckhed F, Cani PD (2011) Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 7(11):639–646. https://doi.org/10.1038/nrendo.2011.126
Hou K, Wu Z-X, Chen X-Y, Wang J-Q, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, Chen Z-S (2022) Microbiota in health and diseases. Sig Transduct Target Ther 7(1):1–28. https://doi.org/10.1038/s41392-022-00974-4
Awad A, Madla CM, McCoubrey LE, Ferraro F, Gavins FKH, Buanz A, Gaisford S, Orlu M, Siepmann F, Siepmann J, Basit AW (2022) Clinical translation of advanced colonic drug delivery technologies. Adv Drug Deliv Rev 181:114076. https://doi.org/10.1016/j.addr.2021.114076
McCoubrey LE, Favaron A, Awad A, Orlu M, Gaisford S, Basit AW (2023) Colonic drug delivery: formulating the next generation of colon-targeted therapeutics. J Control Release 353:1107–1126. https://doi.org/10.1016/j.jconrel.2022.12.029
Hua S (2020) Advances in oral drug delivery for regional targeting in the gastrointestinal tract influence of physiological pathophysiological and pharmaceutical factors. Frontiers Pharmacol. https://doi.org/10.3389/fphar.2020.00524
Dobson PD, Patel Y, Kell DB (2009) ‘Metabolite-likeness’ as a criterion in the design and selection of pharmaceutical drug libraries. Drug Discovery Today 14(1–2):31–40. https://doi.org/10.1016/j.drudis.2008.10.011
O′Hagan S, Swainston N, Handl J, Kell DB (2015) Rule of 05’ for the metabolite-likeness of approved pharmaceutical. Drugs Metab 11(2):323–339. https://doi.org/10.1007/s11306-014-0733-z
O’Hagan S, Kell DB (2017) Analysis of drug-endogenous human metabolite similarities in terms of their maximum common substructures. J Cheminform 9(1):18. https://doi.org/10.1186/s13321-017-0198-y
Bofill A, Jalencas X, Oprea TI, Mestres J (2019) The Human endogenous metabolome as a pharmacology baseline for drug discovery. Drug Discovery Today 24(9):1806–1820. https://doi.org/10.1016/j.drudis.2019.06.007
Dobson PD, Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7(3):205–220. https://doi.org/10.1038/nrd2438
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1PII of original article S0169-409X(96)00423-1: the article was originally published in. Adv Drug Delivery Rev 23:3–25
Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45(12):2615–2623. https://doi.org/10.1021/jm020017n
van Laan MJ, Polley EC, Hubbard AE (2007) Super learner. Stat Appl Genet Mol Biol. https://doi.org/10.2202/1544-6115.1309
RDKit: Open-source cheminformatics. https://www.rdkit.org/ (Accessed 09 Mar 2021).
Wishart DS, Guo A, Oler E, Wang F, Anjum A, Peters H, Dizon R, Sayeeda Z, Tian S, Lee BL, Berjanskii M, Mah R, Yamamoto M, Jovel J, Torres-Calzada C, Hiebert-Giesbrecht M, Lui VW, Varshavi D, Varshavi D, Allen D, Arndt D, Khetarpal N, Sivakumaran A, Harford K, Sanford S, Yee K, Cao X, Budinski Z, Liigand J, Zhang L, Zheng J, Mandal R, Karu N, Dambrova M, Schiöth HB, Greiner R, Gautam V (2022) HMDB 5.0: the human metabolome database for 2022. Nucl Acids Res 50(D1):D622–D631. https://doi.org/10.1093/nar/gkab1062
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M (2018) DrugBank 5.0: a major update to the drugbank database for 2018. Nucleic Acids Res 46(D1):D1074–D1082. https://doi.org/10.1093/nar/gkx1037
Bento AP, Hersey A, Félix E, Landrum G, Gaulton A, Atkinson F, Bellis LJ, De Veij M, Leach AR (2020) An open source chemical structure curation pipeline using RDKit. J Cheminform 12(1):51. https://doi.org/10.1186/s13321-020-00456-1
Kaya I, Colmenarejo G (2020) Analysis of nuisance substructures and aggregators in a comprehensive database of food chemical compounds. J Agric Food Chem 68(33):8812–8824. https://doi.org/10.1021/acs.jafc.0c02521
Sánchez-Ruiz A, Colmenarejo G (2021) Updated prediction of aggregators and assay-interfering substructures in food compounds. J Agric Food Chem 69(50):15184–15194. https://doi.org/10.1021/acs.jafc.1c05918
Sánchez-Ruiz A, Colmenarejo G (2022) Systematic analysis and prediction of the target space of bioactive food compounds: filling the chemobiological gaps. J Chem Inf Model 62(16):3734–3751. https://doi.org/10.1021/acs.jcim.2c00888
Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, Wishart DS (2016) classyfire: automated chemical classification with a comprehensive, computable taxonomy. J Cheminform 8(1):61. https://doi.org/10.1186/s13321-016-0174-y
Bemis GW, Murcko MA (1996) The properties of known drugs 1 molecular frameworks. J. Med. Chem. 39(15):2887–2893. https://doi.org/10.1021/jm9602928
Bemis GW, Murcko MA (1999) Properties of known drugs 2 side chains. J Med Chem 42(25):5095–5099. https://doi.org/10.1021/jm9903996
Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL (2012) Quantifying the chemical beauty of drugs. Nature Chem 4(2):90–98. https://doi.org/10.1038/nchem.1243
Shan G, Gerstenberger S (2017) Fisher’s exact approach for post hoc analysis of a Chi-Squared test. PLoS ONE 12(12):e0188709. https://doi.org/10.1371/journal.pone.0188709
McGraw KO, Wong SP (1992) A common language effect size statistic. Psychol Bull 111:361–365. https://doi.org/10.1037/0033-2909.111.2.361
Butina D (1999) unsupervised data base clustering based on daylight’s fingerprint and tanimoto similarity: a fast and automated way to cluster small and large data sets. J Chem Inf Comput Sci 39(4):747–750. https://doi.org/10.1021/ci9803381
The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. Elsevier Enhanced Reader. https://doi.org/10.1016/S0021-9258(18)52203-1.
Lipinski CA (2004) Lead—and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1(4):337–341. https://doi.org/10.1016/j.ddtec.2004.11.007
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23(1):3–25. https://doi.org/10.1016/S0169-409X(96)00423-1
Alqahtani S (2017) In silico ADME-tox modeling: progress and prospects. Expert Opin Drug Metab Toxicol 13(11):1147–1158. https://doi.org/10.1080/17425255.2017.1389897
Colmenarejo G (2005) In silico ADME prediction: data sets and models. CAD 1(4):365–376. https://doi.org/10.2174/157340905774330318
Kar S, Leszczynski J (2020) Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opin Drug Discov 15(12):1473–1487. https://doi.org/10.1080/17460441.2020.1798926
Ghose AK, Viswanadhan VN, Wendoloski JJA (1999) Knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery 1 a qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1(1):55–68. https://doi.org/10.1021/cc9800071
Murota K (2020) Digestion and absorption of dietary glycerophospholipids in the small intestine: their significance as carrier molecules of choline and n-3 polyunsaturated fatty acids. Biocatal Agric Biotechnol 26:101633. https://doi.org/10.1016/j.bcab.2020.101633
Schmelz E-M, Crall KJ, Larocque R, Dillehay DL, Merrill AH (1994) Uptake and metabolism of sphingolipids in isolated intestinal loops of mice 1,2,3. J Nutr 124(5):702–712. https://doi.org/10.1093/jn/124.5.702
Di L, Kerns EH (2016) Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization, 2nd edn. Elsevier/AP, Amsterdam Boston
Zheng X, Cai X, Hao H (2022) Emerging targetome and signalome landscape of gut microbial metabolites. Cell Metab 34(1):35–58. https://doi.org/10.1016/j.cmet.2021.12.011
Song X, An Y, Chen D, Zhang W, Wu X, Li C, Wang S, Dong W, Wang B, Liu T, Zhong W, Sun T, Cao H (2022) Microbial metabolite deoxycholic acid promotes vasculogenic mimicry formation in intestinal carcinogenesis. Cancer Sci 113(2):459–477. https://doi.org/10.1111/cas.15208
Agus A, Clément K, Sokol H (2021) Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut 70(6):1174–1182. https://doi.org/10.1136/gutjnl-2020-323071
Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, Wallace O, Weir A (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 14(7):475–486. https://doi.org/10.1038/nrd4609
Dvořák Z, Kopp F, Costello CM, Kemp JS, Li H, Vrzalová A, Štěpánková M, Bartoňková I, Jiskrová E, Poulíková K, Vyhlídalová B, Nordstroem LU, Karunaratne CV, Ranhotra HS, Mun KS, Naren AP, Murray IA, Perdew GH, Brtko J, Toporova L, Schön A, Wallace BD, Walton WG, Redinbo MR, Sun K, Beck A, Kortagere S, Neary MC, Chandran A, Vishveshwara S, Cavalluzzi MM, Lentini G, Cui JY, Gu H, March JC, Chatterjee S, Matson A, Wright D, Flannigan KL, Hirota SA, Sartor RB, Mani S (2020) Targeting the pregnane x receptor using microbial metabolite mimicry. EMBO Mol Med 12(4):e11621. https://doi.org/10.15252/emmm.201911621
Grycová A, Joo H, Maier V, Illés P, Vyhlídalová B, Poulíková K, Sládeková L, Nádvorník P, Vrzal R, Zemánková L, Pečinková P, Poruba M, Zapletalová I, Večeřa R, Anzenbacher P, Ehrmann J, Ondra P, Jung J-W, Mani S, Dvořák Z (2022) Targeting the aryl hydrocarbon receptor with microbial metabolite mimics alleviates experimental colitis in mice. J Med Chem 65(9):6859–6868. https://doi.org/10.1021/acs.jmedchem.2c00208
Dvořák Z, Li H, Mani S (2023) Microbial metabolites as ligands to xenobiotic receptors: chemical mimicry as potential drugs of the future. Drug Metab Dispos 51(2):219–227. https://doi.org/10.1124/dmd.122.000860
Nuzzo A, Saha S, Berg E, Jayawickreme C, Tocker J, Brown JR (2021) Expanding the drug discovery space with predicted metabolite-target interactions. Commun Biol 4(1):1–11. https://doi.org/10.1038/s42003-021-01822-x
Wolpert DH (1992) Stacked generalization. Neural Netw 5(2):241–259. https://doi.org/10.1016/S0893-6080(05)80023-1
Butler KT, Davies DW, Cartwright H, Isayev O, Walsh A (2018) Machine learning for molecular and materials science. Nature 559(7715):547–555. https://doi.org/10.1038/s41586-018-0337-2
Gómez-Bombarelli R, Aspuru-Guzik A (2018) Machine learning and big-data in computational chemistry. In: Yip SW (ed) Handbook of materials modeling methods theory and modeling Andreoni. Springer International Publishing, Cham
Mayr A, Klambauer G, Unterthiner T, Steijaert M, Wegner JK, Ceulemans H, Clevert D-A, Hochreiter S (2018) Large-scale comparison of machine learning methods for drug target prediction on ChEMBL. Chem Sci 9(24):5441–5451. https://doi.org/10.1039/C8SC00148K
Niazi SK, Mariam Z (2023) Recent advances in machine-learning-based chemoinformatics: a comprehensive review. Int J Mol Sci 24(14):11488. https://doi.org/10.3390/ijms241411488
Heikamp K, Bajorath J (2014) Support vector machines for drug discovery. Expert Opin Drug Discov 9(1):93–104. https://doi.org/10.1517/17460441.2014.866943
Zernov VV, Balakin KV, Ivaschenko AA, Savchuk NP, Pletnev IV, Drug Discovery Using Support Vector Machines (2003) The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions. J Chem Inf Comput Sci 43(6):2048–2056. https://doi.org/10.1021/ci0340916
Lévêque L, Tahiri N, Goldsmith M-R, Verner M-A (2022) Quantitative structure-activity relationship (QSAR) modeling to predict the transfer of environmental chemicals across the placenta. Comput Toxicol 21:100211. https://doi.org/10.1016/j.comtox.2021.100211
Kumar N, Acharya V (2022) Machine intelligence-driven framework for optimized hit selection in virtual screening. J Cheminform 14(1):48. https://doi.org/10.1186/s13321-022-00630-7
Cova TFGG, Pais AACC (2019) Deep learning for deep chemistry: optimizing the prediction of chemical patterns. Front Chem. https://doi.org/10.3389/fchem.2019.00809
Sinha K, Ghosh N, Sil PC (2023) A review on the recent applications of deep learning in predictive drug toxicological studies. Chem Res Toxicol 36(8):1174–1205. https://doi.org/10.1021/acs.chemrestox.2c00375